Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 18/20 | 0.47 |
| ▸ | GSK3B | P49841 | 18/20 | 0.47 |
| ▸ | CDK2 | P24941 | 4/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | MYLK | Q15746 | 1/20 | 0.42 |
| ▸ | MARK1 | Q9P0L2 | 1/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.42 |
| ▸ | ULK1 | O75385 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23356109 | 0.99 | GSK3A (0.47) | GSK3AGSK3BCDK2ADORA2AADORA1 | |
| SCHEMBL30791235 | 0.99 | GSK3A (0.47) | GSK3AGSK3BCDK2ADORA2AADORA1 | |
| SCHEMBL30791290 | 0.86 | ALDH1A1 (0.42) | ULK1 | |
| SCHEMBL23356047 | 0.86 | ALDH1A1 (0.42) | ULK1 | |
| SCHEMBL30791240 | 0.82 | L3MBTL1 (0.54) | GSK3BCDK2ULK1 | |
| SCHEMBL23356088 | 0.82 | L3MBTL1 (0.54) | GSK3BCDK2ULK1 | |
| SCHEMBL23356090 | 0.81 | NISCH (0.42) | ULK1 | |
| SCHEMBL30791245 | 0.81 | NISCH (0.42) | ULK1 | |
| SCHEMBL23356124 | 0.81 | RXRA (0.42) | ULK1 | |
| SCHEMBL23356014 | 0.80 | NISCH (0.43) | ULK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220259199-A1 | NOVEL HETEROCYCLE DERIVATIVE | JW PHARMACEUTICAL CORPORATION (KR) | 2022-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220259199-A1 | NOVEL HETEROCYCLE DERIVATIVE | AR, BRDT, NR5A1 | GSK3A 1526/4885GSK3B 1258/4885CDK2 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.